Cleveland Clinic staff psychiatrist and psychedelic trialist Brian Barnett sits down with Psychedelic Alpha’s Josh Hardman to discuss psychiatrists’ perceptions of the field, the role of ketamine in ‘...

Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.

A Pα+ tool that allows you to monitor the status of psychedelics-related bills working their way through both state and federal legislatures in the U.S.

Ipsos research examines information pathways and attitudes regarding the use of psychedelics in mental health treatment

Gilgamesh Prints Positive Topline from Phase 2a Study of NMDA Receptor Agonist for MDD • FDA Lifts Hold on GH Research’s Inhaled 5-MeO-DMT IND After More than Two Years • Cybin Rebrands to Helus…

In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questions and potential futures in the psychedelics field via a narrated presentation.

In the first of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look back at 2025 via a narrated presentation. In this hour-long video, Hardman reviews developments across psychedelic…

Australia’s Department of Veterans’ Affairs Explains World-First Funding Model for Psychedelic-Assisted Psychotherapy • New Mexico Targets December 2026 for Medical Psilocybin Launch •

Psychedelic Alpha’s Josh Hardman reports from Washington, D.C., where conversations with regulators, lawmakers, and insiders suggest a turbulent but potentially transformative period ahead.

Psychedelic Alpha’s Josh Hardman sits down with Compass Pathways’ Chief Patient Officer, Steve Levine, at a pivotal time for the company. In this wide-ranging discussion, the pair cover these…

The Advanced Research Projects Agency for Health (ARPA-H) has carved out up to $100M for an initiative that aims to develop objective measures of mental and behavioural health, it announced today.

Largest LSD Microdosing Trial to Date Fails Across All Endpoints • AtaiBeckley’s Phase 2b Debrief: More Detail on SAE and Phase 3 Considerations • UK Government Holds Line on Psilocybin Despite New…

In this interview with Psychedelic Alpha’s Josh Hardman, psychiatrist, therapist and researcher Dr. Óscar Soto discusses psychedelic trial design, therapeutic fidelity, and the evolving role of…

This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD)…

Compass Accelerates Psilocybin Launch Plans by Almost a Year • Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans • AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidat...

This morning, Compass Pathways announced that it is preparing to launch its psilocybin therapy (COMP360) for treatment-resistant depression (TRD) at least nine months earlier than previously planned…

Delix Therapeutics Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II • NRx Pharmaceuticals Wants FDA to Ban Its Competitors’ Ketamine •

Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.

AbbVie Officially Enters Psychedelics as Gilgamesh Deal Closes, Patent Dispute Opens • BPL-003 Wins Breakthrough Status as atai Raises $150M • FDA Passes on Psychedelics in First Round of Priority Vou...

Psychedelic Alpha’s Josh Hardman speaks with Robert Schoevers, Head of Psychiatry at University Medical Center Groningen and principal investigator of the EU-funded PsyPal study, about growing public ...

Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical…

Welcome to the inaugural issue of The Psychedelic Practitioner, a new publication for the evolving practice of psychedelic care.

Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.

MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…

This morning, the UK’s Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related…

We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q3’2025.

From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer…

Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the…

FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.

Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •

This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine in treatment-resistant depression. Here, we break the news…

Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.

This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deepe...

Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute.

Q2’25 Psychedelic Lobbying Update • Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find • UK Moves Toward Easing Schedule I Research Restrictions But Keeps…

Psychedelic Alpha’s Charles Bliss speaks with Professor Celia Morgan, a leading ketamine researcher, about the promise of ketamine-assisted therapy for alcohol use disorder…

AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Dra...